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with no adverse effects reported. One 
patient treated herself with albenda-
zole (400 mg/day for 3 days) before 
she was seen at a hospital. All patients 
became asymptomatic and had nega-
tive stool examination results 2–10 
weeks after treatment. 
None of the patients reported pre-
vious or subsequent consumption of 
raw freshwater ﬁ  sh. Raw ﬁ  sh prepara-
tions such as sushi, sashimi, carpaccio, 
and ceviche are increasingly popular 
and are now also prepared with local 
freshwater ﬁ  sh. These new food habits 
represent a clear risk factor for human 
infection (5,7).
The plerocercoid larvae in the ﬁ  sh 
muscles are easily missed during food 
preparation. Nor are local ﬁ  sh system-
atically inspected, as imported ﬁ  sh are. 
The role of paratenic hosts (e.g., dogs, 
foxes) in transmission is not fully un-
derstood. 
Information given to the public 
and professionals such as food han-
dlers, restaurant owners, and ﬁ  sher-
men is a key measure to promote 
safer food practices. Avoiding serving 
preparations of raw freshwater ﬁ  sh or 
selecting ﬁ  sh that are not intermedi-
ate hosts of D. latum would decrease 
parasite transmission. Cooking the 
ﬁ  sh at 55°C for 5 minutes efﬁ  ciently 
kills the larvae. Freezing the ﬁ  sh at 
–20°C for 24 hours is also efﬁ  cient. 
International regulations recommend 
freezing all ﬁ  sh that are expected to 
be served raw. Notable exceptions 
are ﬁ  sh from farm culture or from ar-
eas where strong evidence proves no 
source or cases of infection (European 
community rules 853/2004 annexe III, 
available from www.paquethygiene.
com/reglement_ce_853_2004/regle-
ments_ce_853_2004_du_parlement_
europeen_et_du_conseil_annexe_
3_section_8.asp#debut). However, 
enforcing these rules proves very dif-
ﬁ  cult for food safety administrations. 
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Human 
Papillomavirus 
Vaccination 
Strategies
To the Editor: An article by El-
basha et al. in the January 2007 is-
sue of Emerging Infectious Diseases 
showed an economic evaluation of 
human papillomavirus (HPV) vac-
cination strategies (1). In this model, 
incremental cost-effectiveness ratio 
(ICER) calculations were based on 
costs measured as US dollars for 2005 
and effectiveness measured as quality-
adjusted life years (QALYs). Authors 
presented these data transparently 
and showed costs and QALYs of each 
strategy in 2 tables, where they did 
not show ICER of dominated options; 
i.e., “Strategy A is dominated if there 
is another strategy, B, that is more ef-
fective and less costly than strategy A” 
(1). Unfortunately, splitting data into 2 
tables can be misleading.
First, ICERs of strategies for vac-
cination at the age of 12 (70% cover-
age) compared with a strategy of no 
vaccination showed that the strategy 
of vaccinating 12-year-old girls and 
boys is dominated by other strate-
gies. Furthermore, vaccination of 12-
year-old girls only and vaccination of 
12-year-old girls only with catch-up 
(vaccination of girls and women 12–
24 years of age) have lower ICERs, 
which could be interpreted as the most 
cost-effective approaches.
Finally, ICERs of strategies of 
vaccinating at 15 and 18 years of age 
(50% coverage) are presented with-
out comparison strategies. Thus, one 
might assume that these strategies 
are compared with the baseline strat-
egy (vaccination of 12-year-old girls 
only); however, they are compared 
with the no-vaccination strategy.
The transparency of the Elbasha 
et al. article enabled us to build a new 
table based on their data (Table). In 
our table, ICERs of the whole set of 
strategies showed that vaccination of 
1958  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 12, December 2007LETTERS
12-year-old girls only is dominated by 
the vaccination of 18-year-old wom-
en plus a catch-up strategy (women 
18–24 years of age), although older 
groups have lower coverages.
In addition, I point out 2 particu-
lars. First, epidemiology of HPV var-
ies between countries (2), probably 
because of differences in culture and 
sexual habits. Thus, vaccination at 
older ages should be considered in 
countries in which prevalence of ado-
lescent sexual activity or HPV is low. 
Second, higher vaccine coverage in 
older groups would decrease ICERs of 
these strategies (1). Both facts could 
reﬂ  ect the real situation in some coun-
tries, e.g., Spain (2,3).
In conclusion, economic evalu-
ations of HPV vaccination strategies 
should have broader sensitivity analy-
sis to include as many country-speciﬁ  c 
realities as possible. To avoid misun-
derstandings that could lead policy-
makers to misallocate funds, these re-
sults should be evident to readers. 
Santiago Pérez Cachafeiro*
*Galician Agency for Health Technology As-
sessment, Santiago de Compostela, Spain
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Distemper in 
a Dolphin 
To the Editor: Deaths caused by 
new members of the genus Morbillivi-
rus, family Paramyxoviridae (1), have 
occurred in recent decades among pho-
cine and cetacean species, particularly 
harbor seals (Phoca vitulina) in 1988 
(2) and 2002 (3). Endangered Medi-
terranean striped dolphins (Stenella 
coeruleoalba) died in 1990 and 1991 
(4), and common dolphins (Delphinus 
delphis ponticus) from the Black Sea 
died in 1994 because of infection with 
dolphin morbillivirus (DMV) (5). A 
similar virus caused deaths in bottle-
nose dolphins (Tursiops truncatus) in 
the Gulf of Mexico from 1987 through 
1994 (6). Closely related morbillivi-
ruses caused deaths in harbor porpois-
es (Phocoena phocoena) in European 
waters in 1988 (7) (Porpoise morbilli-
virus) and endangered Mediterranean 
monk seals (Monachus monachus) in 
1997 (8) (Monk seal morbillivirus). 
After these epidemics, the viruses dis-
appeared and no marine or terrestrial 
reservoirs have been identiﬁ  ed.
In January 2007, a moribund, sub-
adult, white-beaked dolphin (Lageno-
rhynchus albirostris) was found 
stranded on the North Friesian coast of 
Germany. The animal was humanely 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 12, December 2007  1959 
Table. Cost-effectiveness analysis of alternative human papillomavirus vaccination strategies* 
Discounted Incremental†
Strategy  Cost QALY Cost QALY 
ICER
($/QALY)‡ 
No vaccination  $72,659,302 2,698,711 – – –
12-y-old girls  $74,042,990 2,699,178 $1,383.688 467 Dominated
18-y-old women + 18–24-y-old female catch-up  $73,553,847 2,699,192 $894,545 481 $1,860
15-y-old girls + 15–24-y-old female catch-up  $73,895,046 2,699,214 $341,199 22 $15,509
12-y-old girls and boys  $78,707,825 2,699,327 $4,812,779 113 Dominated
12-y-old girls + 12–24-y-old female catch-up  $74,815,667 2,699,343 $920,621 129 $7,137
18-y-old women and men + 18–24-y-old female 
and male catch-up 
$77,535,383 2,699,385 $2,719,716 42 $64,755
15-y-old girls and boys + 15–24-y-old female and 
male catch-up 
$78,455,750 2,699,404 $920,367 19 $48,440
12-y-old girls and boys + 12–24-y-old female 
catch-up
$79,746,357 2,699,461 $1,290,607 57 $22,642
12-y-old girls and boys + 12–24-y-old female and 
male catch-up 
$81,761,210 2,699,506 $2,014,853 45 $44,775
*QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; $, US dollars. 
†Based on discounted costs reported by Elbasha et al. (1).
‡Compared with the preceding nondominated strategy. Strategy A is dominated if there exists another strategy, B, that is more effective and less costly 
than strategy A. 
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